

Keytruda® (pembrolizumab) - New warnings

- On July 27, 2017, the <u>FDA approved</u> updates to the *Warnings and Precautions* section of the <u>Keytruda (pembrolizumab)</u> drug label regarding immune-mediated skin adverse reactions and other immune-mediated adverse reactions to include solid organ transplant rejection.
- Keytruda is approved to treat melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high cancer. Refer to the Keytruda drug label for more specific indication information.
- Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur.
 - Patients should be monitored for severe skin reactions and exclude other causes.
 - Based on the severity of the adverse reaction, Keytruda should be withheld or permanently discontinued and corticosteroids administered.
 - For signs or symptoms of SJS or TEN, Keytruda should be withheld and the patient should be referred for specialized care for assessment and treatment.
 - If SJS or TEN is confirmed, Keytruda should be permanently discontinued.
- Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with Keytruda.
 - Treatment with Keytruda may increase the risk of rejection in solid organ transplant recipients.
 - The benefit of treatment with Keytruda should be considered versus the risk of possible organ rejection in these patients.
- In addition, information regarding the adverse skin reactions and possible organ transplant rejection has been added to the *Patient Counseling Information*.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.